Published in J Ment Health Res Intellect Disabil on March 07, 2011
Assessment and treatment in autism spectrum disorders: a focus on genetics and psychiatry. Autism Res Treat (2012) 0.79
A retrospective study of amitriptyline in youth with autism spectrum disorders. J Autism Dev Disord (2013) 0.75
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther (2002) 3.67
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry (2003) 2.83
Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet (2002) 2.77
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry (2009) 2.69
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics (2009) 2.13
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry (2008) 1.89
Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr (2006) 1.55
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology (2002) 1.35
Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry (2003) 1.32
Differential epigenomic and transcriptomic responses in subcutaneous adipose tissue between low and high responders to caloric restriction. Am J Clin Nutr (2009) 1.30
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry (2004) 1.16
Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol (2004) 1.09
Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol (2006) 1.08
Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol (2001) 1.06
Antipsychotics in the treatment of autism. J Clin Invest (2008) 1.06
Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol (2008) 1.03
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res (2008) 1.01
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry (2003) 0.97
A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord (2006) 0.93
Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs (2005) 0.87
Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry (2003) 0.86
Aripiprazole: in adolescents with schizophrenia. Paediatr Drugs (2007) 0.83
Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit (2009) 0.82
Early Prevention of Severe Neurodevelopmental Behavior Disorders: An Integration. J Ment Health Res Intellect Disabil (2012) 0.77